Document is current
Any future updates will be listed below
-
Authors
Planas, Delphine
Veyer, David
Baidaliuk, Artem https://orcid.org/0000-0002-8351-1142
Staropoli, Isabelle
Guivel-Benhassine, Florence
Rajah, Maaran Michael https://orcid.org/0000-0002-6674-8850
Planchais, Cyril
Porrot, Françoise https://orcid.org/0000-0001-8995-3614
Robillard, Nicolas
Puech, Julien
Prot, Matthieu
Gallais, Floriane
Gantner, Pierre
Velay, Aurélie
Le Guen, Julien
Kassis-Chikhani, Najiby
Edriss, Dhiaeddine
Belec, Laurent
Seve, Aymeric
Courtellemont, Laura
Péré, Hélène
Hocqueloux, Laurent https://orcid.org/0000-0002-2264-4822
Fafi-Kremer, Samira
Prazuck, Thierry
Mouquet, Hugo
Bruel, Timothée https://orcid.org/0000-0002-3952-4261
Simon-Lorière, Etienne https://orcid.org/0000-0001-8420-7743
Rey, Felix A. https://orcid.org/0000-0002-9953-7988
Schwartz, Olivier https://orcid.org/0000-0002-0729-1475
- License Information
-
More Information
Article History
Received: 26 May 2021
Accepted: 29 June 2021
First Online: 8 July 2021
Competing interests
: C.P., H.M., O.S, T.B. and F.A.R. have a pending patent application for the anti-RBD monoclonal antibodies described in the present study (PCT/FR2021/070522). F.A.R. is a member of the Board of MELETIOS Therapeutics and of the Scientific Advisory Board of eureKARE. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
